Current trends in the pharmacologic and surgical treatment of Parkinson's disease

Journal of the American Osteopathic Association

Volumn 96, Issue 4, 1996, Pages 228-232

  Galler, Robert Michael ^a,c   Hallas, Brian H ^a   Fazzini, Enrico ^a,b  

^a NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

L dopa; MAO B inhibitor; neural transplants; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GANGLIOSIDE GM1; LAZABEMIDE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PERGOLIDE MESILATE; ROPINIROLE; SELEGILINE; TOCOPHEROL; TYROSINE; TYROSINE 3 MONOOXYGENASE;

ADRENAL MEDULLA; CAUDATE NUCLEUS; CLINICAL TRIAL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG MECHANISM; DRUG MIXTURE; FETAL TISSUE TRANSPLANTATION; GENE THERAPY; GLOBUS PALLIDUS; HUMAN; IMPLANTATION; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; REVIEW; STEREOTAXIC SURGERY;

EID: 0029869149     PISSN: 00986151     EISSN: None     Source Type: Journal    
DOI: 10.7556/jaoa.1996.96.4.228     Document Type: Review

References (25)

1. Cote L, Crutcher MD: Loss of dopaminergic cells leads to Parkinson's disease, in Kandell ER, Schwartz JH, Jessell TM (eds): Principles of Neural Science. New York, NY, Elsevier Science Publishing Co, 1991, pp 645-659.
2. Fazzini E: Transplantation in the treatment of paralysis agitans (Parkinson's disease). JAOA 1992;92:1255-1266.
3. Riederer P, Lange KW: Pathogenesis of Parkinson's disease. Curr Opin Neurol Neurosurg 1992;5:295-300.
4. Fazzini E, Fleming J, Fahn S: Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Mov Disord 1992;7:153-158.
5. Tanner CM, Langsten JW: Do environmental toxins cause Parkinson's disease? A critical review. Neurology 1990;(suppl 3):17-30.
6. Jenner P, Schaipira AHV, Marsden CD: New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
7. Olanow CW: Oxidative reactions in Parkinson's disease. Neurology 1990;40(suppl 3):32-39.
8. Koller WC: Initiating treatment of Parkinson's disease. Neurology 1992;42(suppl 1):33-38.
9. Rodnitzky RL: The use of Sinemet CR in the management of mild to moderate Parkinson's disease. Neurology 1992;42(suppl 1):44-50.
10. Cooper JR, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology. New York, NY, Oxford Press, 1991, pp 328-331.
11. Goetz CG, Diederich NJ: Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin 1992;10:527-540.
12. The Parkinson Study Group: DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-1060.
13. The Parkinson Study Group: The effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 93;328:173-183.
14. Ward CD: Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatr 1994;57:217-220.
15. The Parkinson Study Group: A controlled trial of lazabemide in levodopa treated Parkinson's disease. Arch Neurol 1994;51:342-347.
16. Dogali M, Fazzini E, Kolodny E, et al: Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995;45:753-761.
17. Fazzini E, Dwork AJ, Blum C, et al: Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in four patients with parkinsonism. Arch Neurol 1991;48:813-820.
18. Spencer DD, Robbins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992;327:1541-1548.
19. Widner H, Tetrud J, Rhencrona S, et al: Bilateral mesencephalic grafting in two patients with parkinsonism induced by MPTP. N Engl J Med 1992;327:1556-1563.
20. Gage FH, Kawaja MD, Fisher LJ: Genetically modified cells: Applications for intracerebral grafting. Trends Neurosci 1991;14:328-333.
21. Jiao S, Gurevich V, Wolff JA: Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 1993;362:450-453.
22. Fahn S: Fetal tissue transplantation in Parkinson's disease. N Engl J Med 1992;327:1589-1590.
23. Freed CR, Breeze RE, Rosenberg NL, et al: Survival of implanted fetal dopamine cells and neurological improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992;327:1549-1555.
24. Laitinen LV, Bergenheim T, Hariz MI: Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. Stereotact Funct Neurosurg 1992;58(1-4):14-21.
25. Laitinen LV: Ventroposterolateral pallidotomy. Stereotact Funct Neurosurg 1994;62(1-4):41-52.